CanSino Biologics, Inc. Class H (HK:6185) has released an update.
CanSino Biologics Inc. has announced that its top executives and controlling shareholders plan to purchase additional shares from the open market, signaling their confidence in the company’s growth prospects. The proposed collective investment by the group, which includes the chairman and chief executive, is capped at HK$10 million and is intended for medium-to-long-term holdings, with no plans to sell within six months post-purchase. This strategy underlines the group’s belief in the firm’s long-term value and commitment to its future.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
